OnKure Therapeutics (NASDAQ:OKUR) Trading Down 3.4% – Here’s Why

OnKure Therapeutics (NASDAQ:OKUR)’s share price fell 3.4% on Wednesday . The stock traded as low as $5.62 and last traded at $5.70. 115,599 shares traded hands during trading, a decline of 12% from the average session volume of 131,277 shares. The stock had previously closed at $5.90.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Leerink Partners assumed coverage on OnKure Therapeutics in a research report on Thursday, December 5th. They set an “outperform” rating and a $33.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of OnKure Therapeutics in a report on Friday, November 8th. Oppenheimer assumed coverage on OnKure Therapeutics in a research note on Thursday, October 10th. They issued an “outperform” rating and a $35.00 price objective for the company. Leerink Partnrs raised OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Finally, Lifesci Capital raised shares of OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, October 10th. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $36.00.

OnKure Therapeutics Trading Down 3.4 %

The firm has a 50-day moving average price of $10.96. The company has a market capitalization of $19.06 million, a P/E ratio of -0.47 and a beta of 0.29.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.13). As a group, equities analysts anticipate that OnKure Therapeutics will post -4.05 EPS for the current year.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.